Karyopharm Therapeutics Inc. (KPTI) SVP Christopher Brett Primiano Sells 2,000 Shares of Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) SVP Christopher Brett Primiano sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $22,000.00. Following the completion of the transaction, the senior vice president now directly owns 12,881 shares in the company, valued at $141,691. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Christopher Brett Primiano also recently made the following trade(s):
- On Monday, June 26th, Christopher Brett Primiano sold 805 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.03, for a total transaction of $8,074.15.
- On Tuesday, August 29th, Christopher Brett Primiano sold 2,195 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $21,950.00.
Shares of Karyopharm Therapeutics Inc. (KPTI) opened at 10.86 on Tuesday. The stock’s 50 day moving average is $9.34 and its 200 day moving average is $9.84. Karyopharm Therapeutics Inc. has a 52-week low of $6.27 and a 52-week high of $14.63. The stock’s market cap is $511.92 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The company’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.84) earnings per share. On average, equities analysts expect that Karyopharm Therapeutics Inc. will post ($2.67) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/19/karyopharm-therapeutics-inc-kpti-svp-christopher-brett-primiano-sells-2000-shares-of-stock.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of KPTI. Voya Investment Management LLC increased its stake in Karyopharm Therapeutics by 42.1% during the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $136,000. Trexquant Investment LP bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $202,000. American International Group Inc. increased its stake in Karyopharm Therapeutics by 20.9% during the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $235,000. 58.97% of the stock is owned by institutional investors and hedge funds.
A number of research firms have weighed in on KPTI. Royal Bank Of Canada began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $14.00 target price on the stock. Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, June 24th. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Thursday, July 6th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $15.67.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.